Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term azithromycin therapy in MALT lymphoma (phase II)
2016-001521-13Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azithromycin in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by Medical University of Vienna. Primary endpoint: Objective response rate. Started May 2016; status: completed.
02
Drugs
azithromycin
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2016-001521-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001521-13.